Update on smoking cessation therapies.
As a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.
Glynn
Deirdre A
DA
Department of Medicine, Sligo General Hospital, Republic of Ireland.
Cryan
John F
JF
Kent
Pauline
P
Flynn
Robert A
RA
Kennedy
Marcus P
MP
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D017281:Cost of Illness; D017277:Drug Approval; D014943:Global Health; D006801:Humans; D009017:Morbidity; D009538:Nicotine / Q000009:adverse effects / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D012449:Safety; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D000068580:Varenicline
D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline